Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leuk Lymphoma 2023 Jan;64(1):250-252
Date
10/14/2022Pubmed ID
36226777Pubmed Central ID
PMC10662133DOI
10.1080/10428194.2022.2131416Scopus ID
2-s2.0-85139925753 (requires institutional sign-in at Scopus site)Author List
Othus M, Thomas I, Wang X, Ariti C, Mehta P, Sydenham M, Hills RK, Burnett AK, Nand S, Assouline S, Michaelis LC, Erba HP, Russell N, Kerr KF, Walter RB, Dennis MAuthor
Laura Michaelis MD Chief, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Disease-Free SurvivalHumans
Leukemia, Myeloid, Acute
Prognosis
